# Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy

> **NCT07565415** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Nanfang Hospital, Southern Medical University** · enrollment: 88 (estimated)

## Conditions studied

- Hepatocellular Carcinoma (HCC)
- Cachexia
- Anorexia
- Malnutrition

## Interventions

- **DRUG:** Nanocrystalline megestrol acetate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07565415
- **Lead sponsor:** Nanfang Hospital, Southern Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-22
- **Primary completion:** 2027-09-01
- **Final completion:** 2027-09-01
- **Target enrollment:** 88 (ESTIMATED)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07565415

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07565415, "Nanocrystalline Megestrol Acetate Versus Placebo for Anorexia in Patients With Unresectable Hepatocellular Carcinoma Receiving TACE Combined With Targeted and Immunotherapy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07565415. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*